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1. INTRODUCTION {#edm215-sec-0005}
===============

Diabetic nephropathy (DN) is characterised by a logarithmic increase in the level of urinary albumin, followed by a progressive decline in renal function. It is further characterised by functional changes in the glomerulus, such as glomerular hyperfiltration and expansion of the extracellular matrix in the mesangial areas, as well as by tubular injuries,[1](#edm215-bib-0001){ref-type="ref"}, [2](#edm215-bib-0002){ref-type="ref"} which ultimately result in progressive kidney dysfunction with an increase in the urine albumin‐to‐creatinine ratio (UACR) and reduction in the glomerular filtration rate (GFR). The key modifiable risk factors for DN include hypertension, hyperglycaemia, dyslipidemia and lifestyle factors.[3](#edm215-bib-0003){ref-type="ref"} Albuminuria is typically caused by a defect in the glomerular filtration barrier; however, abnormalities in tubular albumin reabsorption may also contribute to the development of albuminuria.[4](#edm215-bib-0004){ref-type="ref"}

The overexpression of sodium‐glucose cotransporter 2 (SGLT2), which has been observed in human proximal tubular epithelial cells in patients with type 2 diabetes mellitus (T2DM),[5](#edm215-bib-0005){ref-type="ref"} may exacerbate hyperglycaemia. Thus, its inhibition, by SGLT2 inhibitors, improves the degree of hyperglycaemia via an increase in the urinary glucose excretion.[6](#edm215-bib-0006){ref-type="ref"}, [7](#edm215-bib-0007){ref-type="ref"} The overexpression of SGLT2 is suggested to cause damage to the kidney, based on the results of preclinical experiments.[8](#edm215-bib-0008){ref-type="ref"} SGLT2‐mediated glucose entry into tubular cells caused the cell more suscepitible to pro‐apoptotic effects.[8](#edm215-bib-0008){ref-type="ref"} Thus the genetic deletion and pharmacological inhibition of SGLT2, in preclinical diabetes models,[9](#edm215-bib-0009){ref-type="ref"}, [10](#edm215-bib-0010){ref-type="ref"} could attenuate not only the associated glomerular hyperfiltration but also tubular apoptosis and atrophy. Therefore, SGLT2 inhibition is expected to provide beneficial effects in the case of DN.

Recently, 2 large studies showed that SGLT2 inhibitors improve renal outcomes, including the progression of albuminuria.[11](#edm215-bib-0011){ref-type="ref"}, [12](#edm215-bib-0012){ref-type="ref"} Although the specific overexpression of SGLT2 in human proximal tubular epithelial cells has been observed in T2DM patients, the renal tubular effects, via SGLT2 inhibition, have rarely been evaluated. The aim of this study was to investigate the effect of SGLT2 inhibitor, tofogliflozin (TOFO) on the renal tubular indices, according to the degree of albuminuria, in patients with T2DM from phase 2 and phase 3 TOFO studies.

2. METHODS {#edm215-sec-0006}
==========

An integrated analysis was performed on 4 phase 2 and phase 3 TOFO studies (Table [S1](#edm215-sup-0004){ref-type="supplementary-material"}), with a duration of at least 24 weeks, that enroled patients with T2DM, and compared the use of the medication to that of a placebo, or different doses of TOFO. The CSG003JP study (TOFO 10, 20 and 40 mg monotherapy) was a 24‐week randomised, double‐blind, placebo‐controlled, combined phase 2 and 3 study.[13](#edm215-bib-0013){ref-type="ref"} The CSG004JP study (TOFO 20 and 40 mg monotherapy) and the CSG005JP study (TOFO 20 and 40 mg as an add‐on to other oral anti‐diabetic agents) were both 52‐week randomised, controlled, open‐label, phase 3 studies.[14](#edm215-bib-0014){ref-type="ref"} Details of the above study\'s design and results, including patient inclusion and exclusion criteria, have been previously reported.[13](#edm215-bib-0013){ref-type="ref"}, [14](#edm215-bib-0014){ref-type="ref"} The CSG006JP study (TOFO 40 mg as monotherapy or add‐on to sulfonylureas or dipeptidyl peptidase‐4 \[DPP‐4\] inhibitors) was a 24‐week, multicentre, open‐label study. Data from the 24‐week or 52‐week core treatment periods of each study were included in this integrated analysis.

All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The protocols were reviewed and approved by the institutional review board of each participating centre. All patients provided written informed consent before being enroled. This integrated analysis was also reviewed and approved by the institutional review board of St. Mary\'s Hospital.

This was an integrated analysis to evaluate the impact of treatment with TOFO on the renal tubular indices, such as *N*‐acetyl‐beta‐[d]{.smallcaps}‐glucosaminidase (NAG), and beta‐2 microglobulin (beta2MG), according to the degree of albuminuria, using data from subsets of patients with T2DM from 4 prospective phase 2 and phase 3 studies. Participants receiving TOFO were divided into 3 groups, based on their UACR levels at baseline. If the tubular indices and UACR at week 24 were not recorded in a patient, the last post‐baseline value measured before the scheduled visit at week 24, was used as the value at week 24 (using the last‐observation‐carried‐forward procedure). Laboratory variables including glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), serum creatinine and serum cystatin C levels were also evaluated from baseline to week 24. The glomerular indices were calculated from serum creatinine and cystatin C levels. We estimated the eGFR~MDRD~ using the Modification of the Diet in Renal Disease (MDRD) formula for the Japanese population[15](#edm215-bib-0015){ref-type="ref"}, [16](#edm215-bib-0016){ref-type="ref"}and eGFR~Cys~ from the Japanese equation[17](#edm215-bib-0017){ref-type="ref"} were estimated from the serum cystatin C values. The assessments also included effects on body weight, and systolic and diastolic blood pressure (BP) from the baseline to week 24. All measurements made within the groups were assessed using the last‐observation‐carried‐forward procedure.

2.1. Statistical analysis {#edm215-sec-0007}
-------------------------

Subjects receiving TOFO were divided into 3 groups, based on their baseline UACR levels: normoalbuminuria (UACR \<30 mg/gCr), microalbuminuria (UACR 30‐\<300 mg/gCr) and macroalbuminuria (UACR ≥300 mg/gCr) groups. Two participants were excluded from the analysis because their baseline eGFR~MDRD~ values were \<30 mL/min/1.73 m^2^. The changes in the tubular indices, UACR, laboratory variables, body weight and BP were compared from baseline to week 24. The differences across groups were also evaluated to investigate the impact of SGLT2 inhibition on the variables. The difference, according to the degree of albuminuria, in the TOFO 10 mg group was not investigated because the number of the participants was too low. The patient demographics of each group are summarised with appropriate descriptive statistics (means and standard deviation \[SD\] or medians for continuous variables and counts and percentages for categorical variables).

The assessments for HbA1c, FPG and body weight (change from the baseline in the variables, at week 24) were analysed using an analysis of covariance (ANCOVA) model, with the groups as a fixed effect and their baseline values as covariates, to examine the differences across groups and to verify their superiority. The other assessments, excluding the tubular indices and UACR, were analysed using a 1‐sample *t* test from the baseline to week 24. In addition, the differences in the assessments, across the groups, were analysed using ANOVA or a Fisher\'s exact test. The tubular indices and UACR were analysed using the Wilcoxon signed rank test from the baseline to week 24. In addition, the differences in the assessments, across the groups, were analysed with the Kruskal‐Wallis test. Finally, a correlation analysis between the tubular indices and the changes in variables was performed using Pearson product‐moment correlation coefficients. The tubular indices and UACR were log‐transformed with application to the univariate analysis. The (2‐sided) significance level for each test was .05.

3. RESULTS {#edm215-sec-0008}
==========

The 988 participants with eGFR~MDRD~ values \>30 mL/min/1.73 m^2^ were divided into 3 groups---normoalbuminuria (n = 661), microalbuminuria (n = 278), and macroalbuminuria (n = 49) groups---according to their baseline UACR levels. The baseline demographic characteristics that might influence the UACR were significantly different between the groups (Table [1](#edm215-tbl-0001){ref-type="table"}). In particular, the tubular indices---NAG and beta2MG---were significantly higher, whereas the UACR exponentially increased across the groups, according to the severity of DN; both the NAG and beta2MG levels were within their lower ranges in the normoalbuminuria group (Table [1](#edm215-tbl-0001){ref-type="table"}). Renal function, assessed using glomerular indices, decreased with increasing UACR. Similarly, age, glycemic status, systolic BP, and the proportion of concomitant antihypertensive drugs used increased significantly with increasing levels of UACR (across the groups). In contrast, there was no significant difference across the groups, with regard to sex, TOFO dosage, diastolic BP or duration of DM (Table [1](#edm215-tbl-0001){ref-type="table"}). Similar baseline characteristics according to the degree of albuminuria were observed in each dosage of tofogliflozin group (Table [S3](#edm215-sup-0004){ref-type="supplementary-material"}).

###### 

Baseline characteristics of the participants

                                                                          UACR (mg/gCr)                  *P* across groups                                     
  ----------------------------------------------------------------------- ------------------------------ ---------------------------- ------------------------ ---------
  N                                                                       661                            278                          49                       
  Age (y)                                                                 57.7 (10.2)                    59.7 (10.5)                  60.1 (9.9)               .01
  Sex, n male/female                                                      435 / 226                      193 / 85                     33 / 16                  n.s.
  TOFO 10 mg / 20 mg / 40 mg                                              40 / 195 / 426                 15 / 82 / 181                2 / 16 / 31              n.s.
  Body weight (kg)                                                        67.7 (13.7)                    69.3 (14.0)                  72.6 (15.8)              .03
  BMI (kg/m^2^)                                                           25.3 (4.2)                     26.0 (4.3)                   26.5 (4.2)               .01
  HbA1c (%)                                                               8.0 (0.9)                      8.2 (0.9)                    8.3 (1.0)                .001
  HbA1c (mmol/mol)                                                        64.2 (9.5)                     66.5 (10.2)                  67.7 (10.9)              
  Fasting plasma glucose (mg/dL)                                          159.5 (35.4)                   166.9 (35.0)                 171.2 (47.0)             .003
  Fasting plasma glucose (mmol/L)                                         8.9 (2.0)                      9.3 (1.9)                    9.5 (2.6)                
  Systolic BP (mm Hg)                                                     128.4 (13.9)                   133.0 (13.8)                 136.9 (13.3)             \<.0001
  Diastolic BP (mm Hg)                                                    77.1 (9.8)                     78.7 (10.9)                  78.7 (12.6)              n.s.
  Concomitant antihyperglycemic drugs (%)                                 60.1                           62.9                         61.2                     n.s.
  alpha‐GI / Biguanide / DPP‐4I / Glinide / Sulfonylurea / Thiazolidine   64 / 62 / 68 / 16 / 113 / 74   26 / 36 / 35 / 4 / 50 / 24   6 / 1 / 5 / 2 / 15 / 1   --
  Concomitant antihypertensive drugs (%)                                  39.6                           55.4                         67.4                     \<.0001
  ARB / ACEI / CCB / beta‐blockers / diuretics                            195 / 10 / 139 / 19 / 51       118 / 9 / 105 / 13 / 17      23 / 3 / 29 / 2 / 5      --
  Duration of diabetes mellitus (y)                                       6.8 (5.8)                      7.0 (6.0)                    7.5 (5.8)                n.s.
  Creatinine (mg/dL)                                                      0.70 (0.15)                    0.73 (0.21)                  0.87 (0.29)              \<.0001
  eGFR~MDRD~ (mL/min/1.73 m^2^)                                           88.8 (18.7)                    87.6 (23.6)                  74.5 (25.0)              \<.0001
  eGFRcys (mL/min/1.73 m^2^)                                              110.5 (22.5)                   104.4 (26.1)                 86.5 (27.3)              \<.0001
  UACR (mg/gCr)                                                           11.2                           68.3                         775.4                    \<.0001
  UACR (mg/mmolCr)                                                        1.3                            7.7                          87.7                     
  Urinary NAG (U/gCr)                                                     6.4                            8.8                          14.5                     \<.0001
  Urinary NAG (U/mmolCr)                                                  0.7                            1.0                          1.6                      
  Urinary beta‐2MG (mg/gCr)                                               115.2                          161.3                        347.4                    \<.0001
  Urinary beta‐2MG (μg/mmolCr)                                            13.0                           18.2                         39.3                     

ACEI, ACE inhibitor; alpha‐GI, alpha‐glucosidase inhibitor; beta‐2MG, β2 microglobulin; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DPP‐4I, dipeptidyl peptidase‐4 inhibitor; eGFR~MDRD~, estimated glomerular filtration rate; eGFRcys, estimated glomerular filtration rate calculated from cystatin C; HbA1c, glycated haemoglobin; NAG, *N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminidase; TOFO, tofogliflozin; UACR, urine albumin‐to‐creatinine ratio.

Mean (standard deviation).

Median for UACR and tubular indices.

ANOVA across groups for continuous variables. Kruskal‐Wallis test across groups for urinary indices. Fisher\'s exact test across groups for categorical variables.

John Wiley & Sons, Ltd

The NAG (median, +19%) level increased significantly from the baseline to week 24, in the normoalbuminuria group, whereas, in the macroalbuminuria group, a significant reduction in the NAG levels (median, −27%) was observed (Table [2](#edm215-tbl-0002){ref-type="table"}). Additionally, the UACR was significantly reduced in all the groups, and significant differences were observed across the groups (Table [2](#edm215-tbl-0002){ref-type="table"}). A median reduction of approximately 50% in the UACR was observed in the micro‐ and macroalbuminuria groups, while the degree of reduction in the UACR was significant but obscure in the normoalbuminuria group. With regard to glomerular indices, the eGFR~MDRD~ was significantly decreased in the macro‐ and microalbuminuria groups, while significant reduction in the eGFR~Cys~ was found in all 3 groups (Table [2](#edm215-tbl-0002){ref-type="table"}). Significant differences were observed in all the glomerular indices across the groups (Table [2](#edm215-tbl-0002){ref-type="table"}).

###### 

Changes in the urine albumin‐to‐creatinine ratio, tubular indices, and glomerular indices, from baseline to week 24

                                  UACR (mg/gCr)                                  *P* across groups                                                                                
  ------------------------------- ---------------------------------------------- ----------------------------------------------- ------------------------------------------------ ---------
  UACR                                                                                                                                                                            
  N                               658                                            271                                             49                                               \<.0001
  Median (mg/gCr)                 −0.6[\*](#edm215-note-0009){ref-type="fn"}     −26.1[\*\*](#edm215-note-0009){ref-type="fn"}   −323.3[\*\*](#edm215-note-0009){ref-type="fn"}   
  Median (mg/mmolCr)              −0.07[\*](#edm215-note-0009){ref-type="fn"}    −3.0[\*\*](#edm215-note-0009){ref-type="fn"}    −36.6[\*\*](#edm215-note-0009){ref-type="fn"}    
  \%                              −6.5                                           −48.5                                           −49.7                                            
  Urinary NAG                                                                                                                                                                     
  N                               658                                            271                                             49                                               \<.0001
  Median (U/gCr)                  1.2[\*\*](#edm215-note-0009){ref-type="fn"}    −0.07                                           −3.9[\*\*](#edm215-note-0009){ref-type="fn"}     
  Median (U/mmolCr)               0.1[\*\*](#edm215-note-0009){ref-type="fn"}    −0.008                                          −0.4[\*\*](#edm215-note-0009){ref-type="fn"}     
  \%                              18.5                                           −1.2                                            −26.9                                            
  Urinary beta2MG (mg/gCr)                                                                                                                                                        
  N                               658                                            271                                             49                                               n.s.
  Median (mg/gCr)                 4.6                                            −1.4                                            −39.2                                            
  Median (μg/mmolCr)              0.5                                            −0.2                                            −4.4                                             
  \%                              5.2                                            −2.1                                            −13.4                                            
  Creatinine (mg/dL)                                                                                                                                                              
  N                               661                                            278                                             49                                               .0001
  Mean                            0.003                                          0.01[\*](#edm215-note-0009){ref-type="fn"}      0.05[\*\*](#edm215-note-0009){ref-type="fn"}     
  SD                              0.07                                           0.10                                            0.07                                             
  \%                              0.80                                           2.47                                            5.73                                             
  eGFR~MDRD~ (mL/min/1.73 m^2^)                                                                                                                                                   
  N                               661                                            278                                             49                                               .01
  Mean                            −0.3                                           −1.6[\*](#edm215-note-0009){ref-type="fn"}      −4.2[\*\*](#edm215-note-0009){ref-type="fn"}     
  SD                              9.6                                            11.8                                            7.4                                              
  \%                              0.1                                            −1.1                                            −5.5                                             
  eGFRcys (mL/min/1.73 m^2^)                                                                                                                                                      
  N                               658                                            271                                             49                                               .03
  Mean                            −6.6[\*\*](#edm215-note-0009){ref-type="fn"}   −8.6[\*\*](#edm215-note-0009){ref-type="fn"}    −9.0[\*\*](#edm215-note-0009){ref-type="fn"}     
  SD                              11.4                                           12.2                                            11.6                                             
  \%                              −5.7                                           −7.8                                            −10.1                                            

beta2MG, β2 microglobulin; eGFR~MDRD~, estimated glomerular filtration rate; eGFRcys, estimated glomerular filtration rate calculated from cystatin C; NAG, *N*‐acetyl‐β‐[d]{.smallcaps}‐glucosaminidase; n.s., not significant (across groups); UACR, urine albumin‐to‐creatinine ratio.

Median for UACR and tubular indices.

Mean (standard deviation).

One‐sample *t* test (vs baseline). Wilcoxon signed rank test (vs baseline) for urinary indices. ANOVA across groups for continuous variables. Kruskal‐Wallis test across groups for urinary indices.

\**P* \< .05, \*\**P* \< .001 vs baseline.

John Wiley & Sons, Ltd

Significant improvements in the glycemic status (HbA1c and FPG), body weight and systolic BP were confirmed, on comparing the values at baseline and at week 24, with SGLT2 inhibition (Table [S2](#edm215-sup-0004){ref-type="supplementary-material"}). The magnitude of the changes in glycemic status, body weight and BP was similar across the groups (Table [S2](#edm215-sup-0004){ref-type="supplementary-material"}). While the diastolic BP was not reduced significantly in the macroalbuminuria group, significant decreases in the diastolic BP, from the baseline to week 24, were observed in the other groups (Table [S2](#edm215-sup-0004){ref-type="supplementary-material"}). The correlation analysis suggested that the changes in the tubular indices and UACR were associated with their baseline values (Figure [1](#edm215-fig-0001){ref-type="fig"}). Log‐transformed NAG and beta2MG levels were significantly correlated with their corresponding baseline values (NAG, *r* = −.60 and beta2MG, *r* = −.49) (Figure [1](#edm215-fig-0001){ref-type="fig"}). Similarly, the log‐transformed reduction in the UACR was significantly correlated with the baseline UACR (Pearson\'s coefficient, *r* = −.45) (Figure [1](#edm215-fig-0001){ref-type="fig"}). Finally, the drug related adverse events of special interest in each group were evaluated (Table [S5](#edm215-sup-0004){ref-type="supplementary-material"}).

![Correlations between the changes in tubular indices and the urine albumin‐to‐creatinine ratio (UACR), and their baseline levels. A, *N*‐acetyl‐beta‐[d]{.smallcaps}‐glucosaminidase (NAG), (B) Beta‐2 microglobulin (beta2MG), (C) UACR](EDM2-1-e00015-g001){#edm215-fig-0001}

4. DISCUSSION {#edm215-sec-0009}
=============

This is the first study to evaluate the impact of TOFO on the renal tubules, in patients with T2DM, according to the degree of albuminuria. The results clearly showed that logarithmic reductions in the renal tubular indices, via SGLT2 inhibition, were observed in patients with T2DM. Thus, SGLT2 inhibition itself may produce logarithmic improvement not only in the case of albuminuria but also renal tubular injuries.

In recent times, the striking reductions in the relative risk of renal outcomes, including the progression of macroalbuminuria, were observed in the EMPA‐REG OUTCOME trial and CANVAS Program.[11](#edm215-bib-0011){ref-type="ref"}, [12](#edm215-bib-0012){ref-type="ref"} Cherney et al[18](#edm215-bib-0018){ref-type="ref"} speculated that the direct effects of SGLT2 inhibition on albuminuria are not related to the improvements in the HbA1c levels, systolic BP, or body weight. In our study, SGLT2 inhibition resulted in an obscure reduction in the UACR, in the normoalbuminuria group. Prominent reductions in the UACR (approximately 50%) in the micro‐ and macroalbuminuria groups were observed; the degrees of improvement in the HbA1c level, BP, and body weight, in all groups, were similar (Table [S2](#edm215-sup-0004){ref-type="supplementary-material"}). Prominent reductions in the UACR, in the micro‐ and macroalbuminuria groups, were observed as early as week 12 (Figure [2](#edm215-fig-0002){ref-type="fig"}). In addition, a logarithmic reduction in the UACR was significantly correlated with the baseline UACR, in all participants (Figure [1](#edm215-fig-0001){ref-type="fig"}). Furthermore, we showed that significant correlations, similar to those of the UACR, were observed between the changes in the tubular indices (NAG and beta2MG) and their baseline values (Figure [1](#edm215-fig-0001){ref-type="fig"}). Therefore, the effect of these characteristics of SGLT2 inhibition on albuminuria and tubular indices may suggest that SGLT2 inhibition itself is beneficial for the prevention of DN progression.

![The process of the change in tubular indices and the urine albumin‐to‐creatinine ratio (UACR) in each group. A, *N*‐acetyl‐beta‐[d]{.smallcaps}‐glucosaminidase (NAG), (B) Beta‐2 microglobulin (beta2MG), (C) UACR. ●: UACR \<30 mg/gCr, ○: UACR 30‐\<300 mg/gCr, ■: UACR ≥300 mg/gCr, Median](EDM2-1-e00015-g002){#edm215-fig-0002}

We investigated the effects of TOFO on the tubular indices, by DN stages too. NAG levels were significantly reduced in the macroalbuminuria group; however, unexpectedly, they were significantly increased in the normoalbuminuria group (Table [2](#edm215-tbl-0002){ref-type="table"}). Furthermore, we observed significant correlations between the changes in NAG levels and their baseline values (Figure [1](#edm215-fig-0001){ref-type="fig"}). The elevation in the NAG levels, as observed in the normoalbuminuria group, might have been caused by the tubular cells' functional response, as a larger amount of glucose in the urine might have flown into the backward tubule after SGLT2 inhibition. Differences in the response of NAG in each group could be attributed to the balance between the tubular cells' functional response and the improvement in tubular damage. In the macroalbuminuria group, the improvements in the tubular damage were greater than the tubular cells' functional response, suggesting that SGLT2 inhibition might have protective effects on the tubules. Following an increase in the DN stage, the baseline renal tubular indices increased (Table [1](#edm215-tbl-0001){ref-type="table"}); afterwards, SGLT2 inhibition attenuated the resulting abnormalities, by DN stage (Table [2](#edm215-tbl-0002){ref-type="table"}). In all the stages, significant positive correlations were found between changes in the UACR and tubular indices (Figures [S1](#edm215-sup-0001){ref-type="supplementary-material"} and [S2](#edm215-sup-0002){ref-type="supplementary-material"}). This might suggest that there is a common improvement mechanism, through SGLT2 inhibition, underlying the UACR and tubular damage. When the individual DN stages were focused on, the UACR was found to be significantly reduced in the normoalbuminuria group. In the micro‐ and macroalbuminuria groups, in particular, the percentage changes in the UACR were not consistent with those in the tubular indices (Table [2](#edm215-tbl-0002){ref-type="table"}). This finding was supported by the correlation analysis, which suggested that the regression line shifted downward in the micro‐ and macroalbuminuria groups (Figures [S1](#edm215-sup-0001){ref-type="supplementary-material"} and [S2](#edm215-sup-0002){ref-type="supplementary-material"}). In the micro‐ and macroalbuminuria groups, the reductions in the UACR could be attributed to not only the tubular effects but also other glomerular effects including the improved function in mesangial cell and podocyte. Further clinical and preclinical studies need to be conducted for further elucidation.

In our study, greater reductions in the levels of estimated glomerular filtration rate (eGFR) at week 24 were observed, with increasing DN stage (Table [2](#edm215-tbl-0002){ref-type="table"}). Cherney et al[19](#edm215-bib-0019){ref-type="ref"} demonstrated the normalisation of tubuloglomerular feedback (TGF) via empagliflozin, in patients with type 1 DM with absolute hyperfiltration. They also suggested that empagliflozin caused afferent vasodilation and significantly improved intraglomerular hypertension.[20](#edm215-bib-0020){ref-type="ref"} The reduction in the eGFR, in our study, could be attributed to the reset of glomerular hyperfiltration through SGLT2 inhibition, suggesting that anti‐hyperfiltration effects might contribute to reductions in the UACR. Improvements in the relative‐hyperfiltration, induced by SGLT2 inhibition, may impact the UACR through the TGF mechanism. The recovery of the eGFR might be attributed not only to the normalisation of the TGF but also other glomerular effects. In particular, preclinical experiments showed that SGLT2 is expressed in mesangial cells, and that the high uptake of glucose and Na+ through SGLT2, in conditions of hyperglycaemia, caused cellular dysfunction with associated hyperfiltration, while the inhibition of SGLT2 maintained cellular function.[21](#edm215-bib-0021){ref-type="ref"}, [22](#edm215-bib-0022){ref-type="ref"} Furthermore, the pharmacological inhibition of SGLT2 reduced the expansion of the mesangial areas in other experiments.[23](#edm215-bib-0023){ref-type="ref"} Therefore, SGLT2 inhibition might produce an improvement in hemodynamic dysregulation, through the normalisation of TGF and other glomerular effects.

SGLT2 inhibitors are thought to be effective in lowering not only extracellular but also intracellular glucose levels. In the proximal tubular cells, intracellular hyperglycaemia, through SGLT2 overexpression, may increase the activity of polyol and hexosamine pathways, and induce the activation of protein kinase C and accumulation of advanced glycation products.[24](#edm215-bib-0024){ref-type="ref"} The hyperglycaemia‐induced cellular abnormalities might produce oxidative stress, and stimulate the inflammation and fibrosis pathways, leading to tubulointerstitial damage, which might then cause the progression of diabetic complications including glomerular damages. In fact, in the proximal tubular cells, excessive glucose reabsorption causes cellular dysfunction.[25](#edm215-bib-0025){ref-type="ref"} Experimental results show that SGLT2 inhibition weakens the cellular oxidative stress[26](#edm215-bib-0026){ref-type="ref"} and knockdown of SGLT2 by small interfering RNAs (siRNAs) significantly inhibits high glucose‐induced reactive oxygen species generation and advanced glycation end‐products expression in proximal tubular cells.[27](#edm215-bib-0027){ref-type="ref"} The current study showed that logarithmic improvements in the tubular indices were observed according to their baseline values (Figure [1](#edm215-fig-0001){ref-type="fig"}). Therefore, SGLT2 might be the gatekeeper of glucose entry, and its inhibition might prevent the vicious cycle of intracellular hyperglycaemia in tubular cells. From the results of the EMPA‐REG OUTCOME, the effects of a lower dose and a higher dose of the SGLT2 inhibitor on slowing kidney disease progression were similar,[11](#edm215-bib-0011){ref-type="ref"} which suggests that even a lower dose of SGLT2 inhibitor might be able to reduce the progression of diabetic complications through the improvement of intracellular hyperglycaemia. In the current study, reductions in the logarithmic tubular indices and UACR were observed irrespective of the dosage of TOFO (Table [S4](#edm215-sup-0004){ref-type="supplementary-material"}). Therefore, SGLT2 inhibitors are expected to cause marked reductions in tubular indices and the UACR early after the initiation of SGLT2 inhibition, by preventing the vicious cycle caused by intracellular hyperglycaemia.

This study has several limitations. Our study was performed in pooled analyses from 4 tofogliflozin studies, and we did not perform the comparison between placebo and tofogliflozin. Moreover, the number of participants in the current study was smaller, and the assigned dosage of tofogliflozin, in particular, in the macroalbuminuria group was 1‐sided. Further, we did not evaluate the effects of the concomitant medications including antihypertensive and antihyperglycaemic drugs. Moreover, the other parameters to evaluate the tubular and glomerular damages need to be measured and compared with those in healthy participants. Patients with renal insufficiency were excluded; thus, the evaluation in participants with lower eGFR levels and in the subgroups following both the degree of albuminuria and eGFR levels would be needed. Although histological confirmation was not performed, the patients' backgrounds were consistent with those observed in previously conducted studies.[28](#edm215-bib-0028){ref-type="ref"} A further prospective long‐term placebo‐controlled study of larger cohorts, in vitro molecular action, and pharmacological study are required to confirm our presumed explanation.

In conclusion, the use of an sodium‐glucose cotransporter 2 inhibitor logarithmically improved the renal tubular indices like urine albumin‐to‐creatinine ratio. Sodium‐glucose cotransporter 2 inhibitors may represent a promising treatment option for diabetic nephropathy through tubular effects.
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